Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director | November 01, 2023 | November 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date November 01, 2023 · Filed November 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2033-11-01 | Direct | 437,244 |
Reported balance
After 2023-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-01 · Grant · Acquired 437,244 · Balance 437,244 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2023 Filed Nov 3, 2023 16:49 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 437,244 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001493152-23-039339 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,244 Underlying: Common Stock · 437,244 shares Expires 2033-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:33 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 142,657 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001493152-22-032691 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,657 Underlying: Common Stock · 142,657 shares Expires 2032-11-14 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 17:45 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 7,859 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-22-000007 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,472 F1 · shares: On December 31, 2021, the Reporting Person was issued 7,859 shares of common stock, par value $0.0001 per share, pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 16:21 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 90,882 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001493152-21-026991 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,882 Underlying: Common Stock · 90,882 shares Expires 2031-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 18:03 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 6,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-024397 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,613 F1 · shares: On September 30, 2021, the Reporting Person was issued 6,106 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 17:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015878 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,507 F1 · shares: On June 30, 2021, the Reporting Person was issued 10,244 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 17:42 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionSeries B Preferred Stock · Derivative | 6 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000905718-21-000826 · matinasbio_fm4jun192021.xml · derivative · entry 3 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 17:42 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionCommon Stock, par value $0.0001 per share | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000826 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 17:42 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000826 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,263 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| March 31, 2021 Filed Apr 5, 2021 19:25 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 7,560 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000556 · wikler_fm4mar312021.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,863 F1 · shares: On March 31, 2021, the Reporting Person was issued 7,560 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 18:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 11,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-000131 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,303 F1 · shares: On December 31, 2020, the Reporting Person was issued 11,673 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 16:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020923 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 30, 2020 Filed Oct 6, 2020 16:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 20,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-019017 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,630 F1 · shares: On September 30, 2020, the Reporting Person was issued 20,725 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:45 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 20,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-012586 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,905 F1 · shares: On June 30, 2020, the Reporting Person was issued 20,537 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011762 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,368 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:10 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 26,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-005693 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,568 F1 · shares: On March 31, 2020, the Reporting Person was issued 26,450 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock, par value $0.0001 per share | 6,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-000117 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,118 F1 · shares: On December 31, 2019, the Reporting Person was issued 6,994 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Incentive Plan. Such shares vest immediately upon grant. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016454 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 18:12 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock, par value $0.0001 per share | 25,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014914 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,924 F1 · shares: On September 30, 2019, the Reporting Person was issued 25,179 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 18:40 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 18,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-010198 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,745 F1 · shares: On June 30, 2019, the Reporting Person was issued 18,524 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 21, 2019 Filed Oct 2, 2019 18:12 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014914 · ownership.xml · nonDerivative · entry 2 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,124 F2 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock Read SEC document |
| March 31, 2019 Filed Apr 3, 2019 16:49 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 14,565 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000329 · matinasbio_fm4mar312019.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,221 F1 · shares: On March 31, 2019, the Reporting Person was issued 14,565 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 16:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 26,681 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000018 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,656 F1 · shares: On December 31, 2018, the Reporting Person was issued 26,681 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 08:16 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000906 · matinasbiofm4_oct12018.xml · derivative · entry 2 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 08:16 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000906 · matinasbiofm4_oct12018.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:36 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 19,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000823 · matinasbiofm4_oct12018.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,975 F1 · price: On October 1, 2018, the Reporting Person was granted 19,294 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 29, 2018 Filed Jul 11, 2018 16:28 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 32,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000622 · wikler-matinasfm4_jun292018.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,681 F1 · shares: On June 29, 2018, the Reporting Person was granted 32,259 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. F1 · price: On June 29, 2018, the Reporting Person was granted 32,259 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:33 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries B Convertible Preferred Stock · Derivative | 6 | $1,000.00 Strike: $0.50 | $6,000.00 |
DisclosureSEC source: 0000905718-18-000586 · wikler-matinasfm4_jun212018.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_date: On June 21, 2018, the Reporting Person purchased six shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F1 · derivative.expiration_date: On June 21, 2018, the Reporting Person purchased six shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| April 30, 2018 Filed May 2, 2018 17:10 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000905718-18-000450 · wiklerfm4_apr302018.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-04-29 F1 · derivative.exercise_date: 25% of the shares on April 30, 2019 and the remaining shares vest in equal monthly installments over the next 36 months. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 17:15 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 18,422 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000363 · wiklermatinasfm4_mar302018.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,422 F1 · shares: On March 30, 2018, the Reporting Person was issued 18,422 shares of common stock par value $.0001 per share which vest immediately upon grant. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 17:35 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000905718-18-000033 · wiklermatinasfm4_jan22018.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2018-01-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on February 2, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| January 02, 2018 Filed Aug 13, 2018 16:00 UTC Amendment | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000905718-18-000731 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-01-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on February 2, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.